mechanism 669 words KG: Als
Contents

mitochondrial-dysfunction-als

Mechanism Info
NameAls
Key Genes/Proteins5-HT1AR, 6-OHDA, A2M, AADC, ABCA1, ABCA2

No AI portrait yet

Knowledge Graph

Agent Input

Related Hypotheses (137)

Orexin-Microglia Modulation Therapy
Score: 0.71
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.71
Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulat
Score: 0.71
Microglial Efferocytosis Enhancement via GPR32 Superagonists
Score: 0.70
Mitochondrial Transfer Pathway Enhancement
Score: 0.70
Complement C1q Mimetic Decoy Therapy
Score: 0.69
Reelin-Mediated Cytoskeletal Stabilization Protocol
Score: 0.69
Cross-Seeding Prevention Strategy
Score: 0.69
Hypocretin-Neurogenesis Coupling Therapy
Score: 0.69
CX43 hemichannel engineering enables size-selective mitochon
Score: 0.69
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
Pericyte Contractility Reset via Selective PDGFR-β Agonism
Score: 0.68
R-Loop Resolution Enhancement Therapy
Score: 0.68
Osmotic Gradient Restoration via Selective AQP1 Enhancement
Score: 0.68
Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution
Score: 0.68
Complement C1QA Spatial Gradient in Cortical Layers
Score: 0.68
RAB27A-dependent extracellular vesicle engineering for mitoc
Score: 0.67
Partial Neuronal Reprogramming via Modified Yamanaka Cocktai
Score: 0.67
Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli
Score: 0.67
Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu
Score: 0.67
← Prevpg 5/7Next →

Related Analyses (30)

TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed

Related Experiments (25)

Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40

See Also (2)

A2M Gene
gene · KG edge: interacts_with
ABCA1 - ATP-Binding Cassette Transporter A1
gene · KG edge: activates

Knowledge Graph (12 edges)

CACNA1A associated_with Als
CHAT associated_with Als
MAP2 interacts_with Als
MAP1B interacts_with Als
MAP6 interacts_with Als
MAPT regulates Als
MAP6 associated_with Als
BACE1 therapeutic_target Als
DCX interacts_with Als
CDK5 activates Als

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...